340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

Suit Filed Over Reduced-Price Vaccines Through 340B Prime Vendor

For-profit clinic says voluntary discounts for safety-net providers are unfair
 

Print Article

November 14, 2012—A private, for-profit immunization clinic in Las Vegas has filed a federal lawsuit seeking to stop GlaxoSmithKline (GSK) from selling vaccines to a Nevada local public health entity at voluntarily discounted prices negotiated by the 340B Prime Vendor Program (PVP).

In an Oct. 25 complaint filed in federal district court in Las Vegas, The Vaccine Center argues that the voluntary price reductions on GSK vaccines that Southern Nevada Health District obtains through its participation in PVP represents unlawful price discrimination, monopolization, and restraint of trade under federal and state antitrust laws.[ms-protect-content id=”2799″] The clinic seeks an injunction against the discounts as well as monetary damages from GSK, the health district, and Apexus, the federal contractor that manages PVP.

By statute, 340B drug discounts are unavailable on vaccines. PVP, however, has negotiated voluntary non-340B discounts with four vaccine manufacturers (GSK, Merck, Novartis, and Sanofi-Pasteur) on behalf of its members as a value-added service. The Vaccine Center argues that “there is no such thing as ‘value-added products’ under the laws or regulations that govern the [340B] program” and that PVP and GSK thus “are not permitted to agree amongst themselves to include vaccines under the program.”

Apexus’ current contract with the Health Resources and Services Administration (HRSA) to manage PVP, which was signed in 2009, states that the 340B prime vendor may offer “other value-added catalog items.” Provision of “value-added products and services” is also one of the required elements of the contract’s standards of performance for the prime vendor.

The case is The Vaccine Center v. GlaxoSmithKline (D. Nev. Case 2:12-cv-01849-JCM-PAL).[/ms-protect-content]

 

Follow us on X

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
2 Aug

We are five months away from Medicare price caps taking effect for 10 top-selling drugs under the #IRA. Our latest #340BInsight episode discusses how this will affect covered entities and provides an updated calculator that 340B Health members can use to estimate the price cap…

Reply on Twitter 1951664033473745025 Retweet on Twitter 1951664033473745025 Like on Twitter 1951664033473745025 Twitter 1951664033473745025
340bhealth 340B Health @340bhealth ·
1 Aug

A limited pilot program announced by @HRSAgov would allow some drugmakers to replace upfront #340B discounts with backend rebates. More: http://bit.ly/4ofrSzl.
The program would apply only to the first 10 Medicare drugs subject to price caps in 2026, but HRSA might expand the…

Reply on Twitter 1951305643962355953 Retweet on Twitter 1951305643962355953 Like on Twitter 1951305643962355953 Twitter 1951305643962355953
340bhealth 340B Health @340bhealth ·
28 Jul

Missouri’s law preventing and penalizing drugmaker conditions on pharmacy partnerships can stay in effect, according to a federal judge who dismissed @AbbVie’s petition to halt enforcement of the law.

This is the latest in a series of decisions that uphold upholding such…

Reply on Twitter 1949859205805985915 Retweet on Twitter 1949859205805985915 Like on Twitter 1949859205805985915 Twitter 1949859205805985915
Load More

RSS 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2025 · 340B Health